[Sarcoptes scabiei var. suis in a closed pig breeding and fattening herd and control possibilities after treatment].
On an Austrian pig breeding and finishing farm containing 13,000 pigs a mange prevalence of 38.7% according to the results of the skin scraping and 28.2% based on serology was determined. Due to the insufficient treatment (single treatment of the sows using Phoxim [Sebacil pour on]), sustainable control was impossible. That could be confirmed by the high number of mange positive gilts and finishing pigs. Before eradication started the following prevalences of mange could be found: sows 6.74% (skin scrapings), respectively 6.18% (serologically), gilts 18.18% resp 28.67%, finishing pigs 54.35% and 38.58%. The breeding stock for eradication was treated with doramectin (Dectomax) injectable solution and the finishing pigs with Ivomec-praemix, both applied twice. The success of treatment of the different farm units and of different age groups was controlled for the following ten months by combined diagnostic methods. In addition to skin scrapings, serum and colostral samples were carried out using a commercially available ELISA licensed for investigation of blood serum and colostrum. After treatment antibodies in the serum of the sows and gilts and Sarcoptes mites in their skin scrapings were detectable for up to four months after treatment. In serum samples of piglets and colostrum samples antibodies against Sarcoptes mites were detectable up to five months after final treatment. Due to the higher level and longer verifiability of antibodies in blood samples of piglets for five months after treatment and high prevalences their use as a diagnostic tool can be recommended. In contrast the use of colostral samples for routine diagnosis should be investigated more thoroughly. The comparison of the results of different diagnostic methods showed that for reliable mange diagnosis combined methods are recommended.
Löwenstein
Michael
M
Department für Pathobiologie, Institut für Parasitologie und Zoologie, VMU Wien. Michael.Loewenstein@vu-wien.ac.at
Ludin
Alexandra
A
Peschke
Roman
R
Kahlbacher
Hermann
H
Schuh
Maximilian
M
D000818:Animals; D000906:Antibodies / Q000097:blood; D001317:Austria / Q000453:epidemiology; D003126:Colostrum / Q000469:parasitology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D007306:Insecticides / Q000627:therapeutic use*; D007559:Ivermectin / Q000031:analogs & derivatives / Q000627:therapeutic use; D008297:Male; D012520:Sarcoptes scabiei / Q000276:immunology*; D012532:Scabies / Q000453:epidemiology / Q000517:prevention & control / Q000662:veterinary*; D012867:Skin / Q000469:parasitology; D013552:Swine; D013553:Swine Diseases / Q000188:drug therapy / Q000453:epidemiology* / Q000517:prevention & control; D016896:Treatment Outcome
D000906:Antibodies; D007306:Insecticides; D007559:Ivermectin; C084101:doramectin